.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Cerilliant
Harvard Business School
Express Scripts
Farmers Insurance
Boehringer Ingelheim
US Department of Justice
Chubb
Julphar
Teva

Generated: September 26, 2017

DrugPatentWatch Database Preview

Clarithromycin - Generic Drug Details

« Back to Dashboard

What are the generic sources for clarithromycin and what is the scope of clarithromycin patent protection?

Clarithromycin
is the generic ingredient in three branded drugs marketed by Ranbaxy, Allied Pharma Inc, Lupin Ltd, Sandoz, Ivax Sub Teva Pharms, Actavis Labs Fl Inc, Idt Australia Ltd, Mayne Pharma, Teva, Abbvie, Wockhardt, Sun Pharm Inds Ltd, West-ward Pharms Int, Apotex Corp, Hec Pharm Usa Inc, Aurobindo, and Mylan, and is included in twenty-three NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Clarithromycin has fifty-seven patent family members in twenty-nine countries.

There are twenty-one drug master file entries for clarithromycin. Forty-one suppliers are listed for this compound.

Summary for Generic Name: clarithromycin

Tradenames:3
Patents:2
Applicants:17
NDAs:23
Drug Master File Entries: see list21
Suppliers / Packagers: see list41
Bulk Api Vendors: see list34
Clinical Trials: see list244
Patent Applications: see list6,255
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:clarithromycin at DailyMed

Pharmacology for Ingredient: clarithromycin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ivax Sub Teva Pharms
CLARITHROMYCIN
clarithromycin
TABLET;ORAL065137-001May 31, 2005DISCNNoNo► Subscribe► Subscribe► Subscribe
Wockhardt
CLARITHROMYCIN
clarithromycin
TABLET;ORAL065266-001May 31, 2006ABRXNoNo► Subscribe► Subscribe► Subscribe
Mayne Pharma
CLARITHROMYCIN
clarithromycin
TABLET, EXTENDED RELEASE;ORAL065154-001May 18, 2005ABRXNoYes► Subscribe► Subscribe► Subscribe
Apotex Corp
CLARITHROMYCIN
clarithromycin
TABLET;ORAL065384-001Aug 20, 2007ABRXNoNo► Subscribe► Subscribe► Subscribe
Abbvie
BIAXIN
clarithromycin
FOR SUSPENSION;ORAL050698-003Sep 30, 1998DISCNNoNo► Subscribe► Subscribe► Subscribe
Actavis Labs Fl Inc
CLARITHROMYCIN
clarithromycin
TABLET, EXTENDED RELEASE;ORAL065145-001Jun 24, 2004ABRXNoNo► Subscribe► Subscribe► Subscribe
Aurobindo
CLARITHROMYCIN
clarithromycin
TABLET;ORAL065489-002Jul 25, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Sandoz
CLARITHROMYCIN
clarithromycin
TABLET;ORAL065136-001Aug 25, 2005ABRXNoNo► Subscribe► Subscribe► Subscribe
Sun Pharm Inds Ltd
CLARITHROMYCIN
clarithromycin
TABLET;ORAL065174-002Sep 24, 2004ABRXNoNo► Subscribe► Subscribe► Subscribe
Ranbaxy
CLARITHROMYCIN
clarithromycin
TABLET, EXTENDED RELEASE;ORAL065210-001Jan 26, 2005DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: clarithromycin

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie
BIAXIN XL
clarithromycin
TABLET, EXTENDED RELEASE;ORAL050775-001Mar 3, 2000► Subscribe► Subscribe
Abbvie
BIAXIN XL
clarithromycin
TABLET, EXTENDED RELEASE;ORAL050775-001Mar 3, 2000► Subscribe► Subscribe
Abbvie
BIAXIN XL
clarithromycin
TABLET, EXTENDED RELEASE;ORAL050775-001Mar 3, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: clarithromycin

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,872,407 Extended release formulations of erythromycin derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: clarithromycin

Country Document Number Estimated Expiration
Australia737324► Subscribe
Israel149033► Subscribe
Japan4394754► Subscribe
New Zealand537410► Subscribe
Norway20021747► Subscribe
Israel223035► Subscribe
Canada2285266► Subscribe
World Intellectual Property Organization (WIPO)9846239► Subscribe
Brazil0010485► Subscribe
Hong Kong1027023► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CLARITHROMYCIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0021Belgium► SubscribePRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Colorcon
Federal Trade Commission
Harvard Business School
Teva
QuintilesIMS
Accenture
Chubb
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot